- Home
- ADCT
ADCT
ADC Therapeutics SA
as 06-20-2025 4:00pm EST
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | EPALINGES |
| Market Cap: | 241.0M | IPO Year: | 2020 |
| Target Price: | $7.80 | AVG Volume (30 days): | 917.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.45 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.05 - $4.13 | Next Earning Date: | 08-05-2025 |
| Revenue: | $75,817,000 | Revenue Growth: | 10.49% |
| Revenue Growth (this year): | 10.65% | Revenue Growth (next year): | 15.05% |
Latest ADC Therapeutics SA News
ADCT Breaking Stock News: Dive into ADCT Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
ADC Therapeutics Announces Updated ZYNLONTA® Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma (ICML)
MT Newswires
9 days ago
ADC Therapeutics to Cut 30% of Workforce, Shutter UK Site
PR Newswire
9 days ago
ADC Therapeutics Announces $100 Million Private Placement Extending Expected Cash Runway into 2028
PR Newswire
9 days ago
ADC Therapeutics Announces Updated Data from LOTIS-7 Clinical Trial Presented at the European Hematology Association 2025 Congress
PR Newswire
19 days ago
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Pharma Voice
22 days ago
AbbVie’s ADC win shows how pharma can break through in solid tumors
Clinical Trials Arena
a month ago
ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data
PR Newswire
a month ago
ADC Therapeutics to Present at Upcoming Investor Conferences
Compare ADCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADCT ADC Therapeutics SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.